Speaking Sessions

December 5, 202109:00 - 10:00

Biografija

EDUCATION:

 

1994-1998 Gymnasium “Jovan Jovanović Zmaj”, in Novi Sad, science and mathematics,

1998-2004 Medical faculty, in Novi Sad, Medicine doctor average 9,39/10.

2008-2011 Specialisation: Internal medicine

2013-2015 Subspecialisation: Oncology

2014 PhD “Significance of molecular markers expression in prognosis of diffuse large B-cell lymphoma treated with immunochemotherapy

 

 

WORKING EXPIRIENCE:

2004-2005 One year intership: Clinic for nephrology and clinical immunology, Clinical Centre of Vojvodina.

2005-2011 Medical doctor: Clinic for medical oncology, Oncology Institute of Vojvodina

2011-2015 Medical doctor, Internal medicine consultant: Clinic for medical oncology, Oncology Institute of Vojvodina

2015-          Medical doctor, Internal medicine consultant, oncology subspecialist: Clinic for medical oncology, Oncology Institute of Vojvodina

2006-2014 Teaching assistent: Department of oncology, Medical faculty, Univeristy of Novi Sad

2014-2019 Assistant Professor:  Department of oncology, Medical faculty, Univeristy of Novi Sad

2019-         Associate Professor:  Department of oncology, Medical faculty, Univeristy of Novi Sad

 

 

FOREIGN LANGUAGES:

English-fluently

German-beginner course (DAAD)

 

EDUCATION and EXPIRIENCE:

 

2008 Professional education: Tenon Hospital, Paris, Medical Oncology and stem cell transplantation unit (Prof Lotz/ Prof Gligorov)

2016 ESMO Clinical Unit Visit Fellowship Grant: Oncology Institute Southern Switzerland, Lymphoma Unit, Breast Cancer Unit, Phase 1 Trials Unit (Prof Cavalli/Prof Ghielmini/Dr Zucca/Dr Pagani/Dr Stathis)

 

2006 Course “Apheresis on Cobe spectra”

2007 GCP course certificate

2012 GCP recerification Quintiles

2008 EBMT-Lymphoma working party training course

2009 EBMT-Infectious diseases working party training course

2011 EBMT-Medical statistics course

2012 Top 10 Teaching assistants at Medical Faculty of Novi Sad-Award of Students

2017 Health Management Academy “Franklin Covey” course

2020 “Olaf & McAteer” Communication with Media Course

 

 

MEMBERSHIPS:

BUON (Balkans Union of Oncology) member

ESMO (European Society for Medical Oncology) member

ESMO YO-National Representative (2015-2019)

SLG (Serbian Lymphoma Study Group) member

SLD (Serbian Medical Society) member                                                                                       

AROME JUNIOR executive board member-research co-ordinator

AJOC (AROME Junior Oncologist Committee)-hematological malignancies co-coordinator (2012-2016)

AROME (Association of Radiotherapy and Oncology in the Mediterranean Area) national board member

NOVI SAD ONCOLOGY CONGRESS 2009., 2010. and 2012. Head of Congress Secretariat

NOVI SAD ONCOLOGY CONGRESS 2014., 2015, 2016, 2017, 2018, 2019 Organizing committee member

NOVI SAD ONCOLOGY CONGRESS 2020 Head of Organizing Committee

ARCHIVE OF ONCOLOGY journal editor 2013-2015, 2017-

ARCHIVE OF ONCOLOGY journal Editor-in-Chief 2015-2017

ONCOLOGY INSTITUE OF VOJVODINA DRG IMPLEMENTATION TEAM 2013-2015

ONCOLOGY INSTITUTE OF VOJVODINA ACREDITATON TEAM (Medical oncology dept and Information technologies teams) 2014-2015

FRONTIERS IN ONCOLOGY Associate Editor (2020-)

 

PROJECTS

 

“Maintaining Quality of Oncology Service in Autonomous Province of Vojvodina”-Educational Project, Ministry of Health, Autonomous Province of Vojvodina 2015-2016

 

 

CLINICAL TRIALS:

 

PRINCIPLE INVESTIGATOR:

 

PHASE III An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with MK-6482 and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First line Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

PHASE III Protocol EV 302: An open- label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer

PHASE II KCP-330-009 A Phase 2B Open-Label Study of Selinexor (KPT-330) in Pateints with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

PHASE III IPATUNITY170 A Phase III, Double-blind, Placebo-controlled, Randomized Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer.

PHASE II MARIO 275 A Phase 2 Multicenter, Randomized, Double Blind, Active Control Study to Evaluate the Efficacy and Safety of Nivolumab Administered in Combination with IPI 549 Compared to Nivolumab Monotherapy in the Treatment of Patients with Immune Therapy Naïve, Advanced Urothelial Carcinoma

PHASE II Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients with Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy

PHASE III A Phase 3, Multicenter, Multinational, Randomized, Open-label, Parallel-arm Study Of Avelumab (msb0010718c) Plus Best Supportive Care Versus Best Supportive Care Alone As A Maintenance Treatment In Patients With Locally Advanced Or Metastatic Urothelial Cancer Whose Disease Did Not Progress After Completion Of First-line Platinum-containing Chemotherapy

PHASE Ib: A Multi-Center, Single-Arm, Open-Label Phase 1b Study of a Novel FGFR3 Inhibitor (B-701) Combined with Pembrolizumab in Subjects with Locally Advanced or Metastatic Urothelial Carcinoma who have Progressed Following Platinum-based Chemotherapy 

PHASE III: The Effect of Atezolizumab in Combination With Gemcitabine/Carboplatin and Gemcitabine/Carboplatin Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Therapy (Imvigor130)

PHASE I: TO-TAS-102-107 A Phase 1, Open-Label, Study to Evaluate the Safety, Tolerabillity, and Pharmacokinetics of TAS-102 in Patients with Advanced Solid Tumors and Varying Degrees of Renal Impairment

PHASE III: A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogeneicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients with Low Tumor Burden Follicular Lymphoma

PHASE III: A Phase III, Open-Label, Multicenter, Randomized Study To Investigate The Efficacy And Safety Of MPDL3280A (Anti−PD-L1 Antibody, Atezolizumab) Compared With Chemotherapy In Patients With Locally Advanced Or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy

PHASE III: A phase 3, multicenter, randomized, double-blind, active control study to evaluate the safety and efficacy of IV pro-netupitant/palonosetron (260 mg/0.25 mg) combination for the prevention of chemotherapy-induced nausea and vomiting in repeated chemotherapy cycles in patients receiving highly emetogenic chemotherapy

PHASE IV: DIREGL07274-Metastatic Castrate Resistant Prostate Cancer-Serbian Registry

 

SUB-INVESTIGATOR:

 

PHASE I: Her-2 positive breast cancer; Aggressive Lymphoma.

PHASE II: Multiple myeloma, Diffuse Large B-Cell Lymphoma, Low Grade Lymphoma

PHASE III: Bladder Cancer-Immunotherapy (anti-PD-L1 adjuvant) , Multiple myeloma, Breast cancer (4 trials); Diffuse Large B-Cell Lymphoma; Follicular Lymphoma; Mantle Cell Lymphoma; Cancer and Coagulation (2 trials), Glioblastoma, Melanoma.

PHASE IV: Diffuse Large B-cell Lymphoma (2 trials), Follicular Lymphoma (2 trials), CLL, Mantle Cell Lymphoma

 

INTERESTS and KNOWLEDGE:

 

Breast cancer

Urological cancers

Lymphoma/CLL

Cancer Immunotherapy

Multiple myeloma

Biomarkers and signaling pathways in cancer

Target therapy

Autologous stem cell transplantation

Supportive care in cancer

Pharmacoeconomy and management

Clinical trials

 

FREE TIME:

Sport: basketball, soccer, swimming

Music: playing drums

 

REFERENCES:

 

BOOKS:

 

Matovina-Brko G, Popovic L Karcinom dojke I gojaznost u Stokic E. Gojaznost je bolest koja se leči (drugi deo) 2018 Medicinski fakultet Novi Sad ISBN 978-86-7197-549-0

 

Cvetanovic A, Popovic L, Zivkovic N, Matovina-Brko G, Filipovic S, Kostic M, Vrbic S, Pejcic I Immune Checkpoint Inhibitors in the Treatment of Solid Tumors: A New Key in the Hands of Oncologists in Watanabe HS Horizons in Cancer Research Vol 65 Nova Science Publishing 2017  ISBN: 978-1-53610-954-2

 

Milic-Torres V, Popovic L, Vaz F, Penque D Proteomics in the Assessment of the Therapeutic Response of Antineoplastic Drugs: Strategies and Practical Applications in Ruef J and Sebastiao Rodrigues Cancer Drug Resistance: Overview and Methods. Methods in Molecular Biology vol 1395 DOI 10.1007/978-1-4939-3347-1_16 Springer Science and Business Media New York 2016

 

Cvetanovic A, Filipovic S, Vrbic S, Pejcic I, Popovic L Side effects of cetuximab: rash in Madison R Hall. Head and neck cancer: epidemiology, management and treatment outcomes Nova Science Publishers 2015 ISBN: 978-1-63482-113-1

 

Popovic L., Grgic Z., Popovic M. “Melanoma during pregnancy” in Armstrong A. Advances in Malignant Melanoma: Clinical and Research Perspectives InTech 2011 ISBN 978-953-307-575-4

 

Lucic S, Lučić M, Peter A, Erak M, Popovic-Petrovic S, Kukić B, Popović L, Đuran B. PET/CT in diagnosis of cancer of unkown primary, Aktuelnosti u u medicini i , stomatologiji i farmaciji: Zbornik radova :Medicinski fakultet Novi Sad 2010 (serbian)

 

 

 

 

PAPERS:

 

Konstantinos Kamposioras, Davide Mauri, Konstantinos Papadimitriou, Alan Anthoney , Nada Hindi , Branka Petricevic,Mario Dambrosio, Antonis Valachis, Pantelis Kountourakis, Jindrich Kopecky,  Cvetka Grašič Kuhar,  Lazar Popovic,Nataliya P. Chilingirova, George Zarkavelis, Ramon Andrade de Mello,  Natalija Dedić Plavetić, Christos Christopoulos,Bianca Mostert, John R. Goffin, Dimitiros Tzachanis, Haytham Hamed Saraireh, Fei Ma,  Ida Pavese, Maria Tolia   Synthesis of Recommendations from 25 countries and 31 Oncology societies-The ball of thread to help navigate the COVID-19 labyrinth Front Oncol (ahead of print) 2020

 

Belkacemi Y, Grellier N, Ghith S, Debbi K, Coraggio G, Bounedjar A, Samlali R, Tsoutsou PG, Ozsahin M, Chauvet MP, Turkan S, Boussen H, Kuten A, Tesanovic D, Errihani H, Benna F, Bouzid K, Idbaih A, Mokhtari K, Popovic L, Spano JP, Lotz JP, Cherif A, To H, Kovcin V, Arsovski O, Beslija S, Dzodic R, Markovic I, Vasovic S, Stamatovic L, Radosavljevic D, Radulovic S, Vrbanec D, Sahraoui S, Vasev N, Stojkovski I, Risteski M, Freixa SV, Krengli M, Radosevic N, Mustacchi G, Filipovic M, Kerrou K, Taghian AG, Todorovic V, Geara F, Gligorov J. A review of the international early recommendations for departments organization and cancer management priorities during the global COVID-19 pandemic: applicability in low- and middle-income countries Eur J Cancer 2020 Aug;135:130-146.

 

Mauri D, Kamposioras K, Tolia M, Alongi F, Tzachanis D…Popovic L Summary of International Recommendations in 23 Languages for Patients With Cancer During the COVID-19 Pandemic International Oncology Panel and European Cancer Patient Coalition Collaborators Lancet Oncol 2020 May 13. doi: 10.1016/S1470-2045(20)30278-3. Online ahead of print.

 

Mauri D, Tzachanis D, Valachis A et al….Popovic L. on behavlf od International Oncology Panel, FAVO end ECPC Behind the numbers and the panic of a viral pandemic: fixed restrictive oncology guidance may jeopardize patients’ survival JBUON 2020; 25(3): 1277-1280

 

Tan A, Wright G, Thummala A, Danso M, Popovic L, Pluard T et al. Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial Lancet Oncol Lancet Oncol. 2019 Nov; 20(11):1587-1601.

 

O’Shaughnessy, Wright G, Thummala A, Danso M, Popovic L, Pluard T et al. Trilaciclib improves overall survival when given with Gemcitabine/Carboplatin (GC) in patients with metastatic triple negative breast cancer (mTNBC) in a randomized phase II trial Ann Oncol 2019: 30 ESMO 2019

 

Vladimir Todorovic, Matti Aapro, Nicholas Pavlidis, Oliver Arsovski, Yazid Belkacemi, Nada Babovic, François Clément Bidard, Mouna Bourhafour, Semir Beslija, Hamouda Boussen, Bojana Cetnikovic, Timur Ceric, Nada Cicmil, Nebojsa Crnogorac, Enkelejda Cuedari, Michele De Laurentis, Tomislav Dragovich, Ivana Durutovic, Zoran Dzamic, Radan Dzodic, Zivka Eri, Fady Geara, Ahmed Khalil, Khaldoun Kerrou, Slavica Knezevic Usaj, Vladimir Kovcin, Dhurata Koroveshi, Anila Kristo Pema, Abraham Kuten, Jadranka Lakicevic, Nevenka Lukovac, Ivan Markovic, Milan Markovic, Nenad Mijalkovic, Daniela Miladinova, Nikola Milasevic, Giorgio Mustachi, Dragana Ognjenovic, Aleksandra Pantelic, Lazar Popovic, Davorin Radosavljevic, Nina Radosevic, Sinisa Radulovic, Milan Ristevski, Ivana Rosic, Nevena Secen, Milan Sorat, Liljana Stamatovic, Petar Stefanovski, Igor Stojkovski, Dusanka Tesanovic, Zorica Tomasevic, Zoran Tomasevic, Pauletta Tsoutsou, Sedat Turkan, Nino Vasev, Suzana Vasovic, Ferenc Vicko, Damir Vrbanec, Filip Vukmirovic, Eduard Vrdoljak, Bojan Zaric, Jean Jacques Zambrovski, Franco Cavalli, Joseph Gligorov AROME-ESO Oncology Consensus Conference: Access to Cancer Care Innovations in Countries With Limited Resources. Association of Radiotherapy and Oncology of the Mediterranean Area (AROME-Paris) and European School of Oncology (ESO – Milan) J BUON 2019; 24 (5): 2180-97

 

Cvetanovic A, Pejcic I, Zivkovic N, Krtinic D, Kostic M, Popovic L Do we really know how to overcome trastuzumab resistance in hormone sensitive metastatic breast cancer? J BUON. 2019 Mar-Apr;24(2):516-521.

 

Popovic M, Matovina-Brko G, Petrovic D, Vranjkovic B, Boskovic-Milosevic B, Popovic L. Prognostic value of age-adjusted international prognostic index in patients with relapsed or refractory diffuse large b-cell lymphoma-single centre experience. 2nd Regional congress of medical oncology, Belgrade , Serbia , May 16-18th 2019. Archive of Oncol 2019;25(suppl 1) p 3.

 

Matovina-Brko G, Popovic M, Trifunovic J, Pesic J, Popovic L. First line treatment of HR+/HER- metastatic breast cancer. 2nd Regional congress of medical oncology, Belgrade , Serbia , May 16-18th 2019. Archive of Oncol 2019;25(suppl 1) p 35.

 

Popović M, Matovina-Brko G, Petrović D, Vranjković B, Radić J , Popović L. Prognostic value of age-adjusted international prognostic index in patients with relapsed or refractory diffuse large B-cell lymphoma- a single centre experience. Med Pregl 2019;LXXII (1-2): 25-29.

J O’Shaughnessy, GS Wright, AR Thummala, MA Danso, L Popovic, TJ Pluard et al. Trilaciclib (T), a CDK4/6 inhibitor, dosed with gemcitabine (G), carboplatin (C) in metastatic triple negative breast cancer (mTNBC) patients: Preliminary phase 2 results Cancer Res 2019; 79 (4, Supplement)

  1. Susnjar, L. Popovic, A. Cvetanovic, N. Stanic, J. Citic, I. Kolarov-Bjelobrk, M. Popovic, N. Nedovic, A. Stojanovic, G. Matovina-Brko, K. Serovic, N. Milosavljevic, Z. Murtezani, I. Kezic, D. Gavrilovic, S. Radulovic Real world data: Trastuzumab w/o concurrent endocrine therapy in luminal HER2-positive metastatic breast cancer resulted in decreased overall survival Eur J Cancer Supp 2018 (ECCO 2018 Poster)

 

Popovic L, Tomasevic Z, Stamatovic L, Markovic I, Matovina-Brko G, Buta M, Golubovic A, Selakovic V, Trifunovic J, Mutrezani Z, Ivanovic N, Nedovic J, Ninkovic S, Filipovic S, Cvetanovic A, Djordjevic N, Karanikolic A, Ivkovic-Kapic T, Vicko F. Serbian consensus of neoadjuvant therapy for breast cancer: NeoPULSE.  J BUON. 2018 Mar-Apr;23(2):522-532.

 

Popovic M,  Matovina-Brko G,  Popovic L,  Vranjkovic B,Novel target and immunotherapy Options in the Treatment of NHL,  9th French Serbian Oncology Congress, Novi Sad. 16-17 march 2018, p 2-3.

 

Popovic L,  Popovic M,  Vranjkovic B,  Matovina-Brko B. Renal Cell Carcinoma Treatment in 2018, 9th French Serbian Oncology Congress, Novi Sad. 16-17 march 2018, p 7.

Todorovic V, Aapro M, Pavlidis N, Arsovski O, Belkacemi Y, Babovic N, Bidard FC, Bourhafour M, Beslija S, Boussen H, Cetnikovic B, Ceric T, Cicmil N, Crnogorac N, Cuedari E, De Laurentis M, Dragovich T, Durutovic I, Dzamic Z, Dzodic R, Eri Z, Geara F, Khalil A, Kerrou K, Knezevic Usaj S, Kovcin V, Koroveshi D, Kristo Pema A, Kuten A, Lakicevic J, Lukovac N, Markovic I, Markovic M, Mijalkovic N, Miladinova D, Milasevic N, Mustachi G, Ognjenovic D, Pantelic A, Popovic L, Radosavljevic D, Radosevic N, Radulovic S, Ristevski M, Rosic I, Secen N, Sorat M, Stamatovic L, Stefanovski P, Stojkovski I, Tesanovic D, Tomasevic Z, Tomasevic Z, Tsoutsou P, Turkan S, Vasev N, Vasovic S, Vicko F, Vrbanec D, Vukmirovic F, Vrdoljak E, Zaric B, Zambrovski JJ, Cavalli F, Gligorov J.  AROME-ESO Oncology Consensus Conference: access to cancer care innovations in countries with limited resources. Association of Radiotherapy and Oncology of the Mediterranean Area (AROME-Paris) and European School of Oncology (ESO – Milan) J BUON. 2019 Sep-Oct;24(5):2180-2197.

 

Cvetanovic A, Filipovic S, Zivkovic N, Popovic L, Kostic M, Djordjevic M, Karanikolic A, Krtinic D. Ten years of using adjuvant trastuzumab in breast cancer in Serbia – Single institution experience.  J BUON. 2018 Mar-Apr;23(2):353-360.

 

Popovic LS, Matovina-Brko G, Popovic M Checkpoint inhibitors in the treatment of urological malignancies ESMO Open. 2017 Jun 23;2(2):e000165.

 

Popovic S, Jovanovic D, Mihaljevic B, Andjelkovic N, Marjanovic G, Marisavljevic D, Vlaisavljevic N, Popovic L, Salma S, Agic D, Milosevic R, Smiljanic M, Sretenović S, Djurdjević P, Markovic O, Hajder J, Govedarovic N Rituximab in the therapy of stage III and IV follicular lymphoma: Results of the REFLECT 1 study of the Serbian Lymphoma Group J BUON. 2017 Mar-Apr;22(2):487-494.

 

Popovic L, Popovic M Editorial Comment to Clinical Analysis Of Severe Psychiatric Disorders In Patients With Testicular Cancer: A Single-Center Experience Int J Urol 2016

 

Popovic Dj, Popovic L Obesity and breast cancer – association even more relevant in males? Eur J Intern Med 2016 Apr;29:e11-2.

 

Popovic L, Matovina-Brko G, Popovic M, Petrovic D, Cvetanovic A, Vukojevic J, Jovanovic D  High dose chemotherapy with stemcell support in the treatment of testicular cancer World J Stem Cells 2015; 7(11): 1222-32

 

Cvetanovic A, Popovic L, Filipovic S, Trifunovic J, Zivkovic N, Matovina-Brko G, Kostic M; Vicko F, Kocic B, Kolarov-Bjelobrk I Young Age and Pathological Features Predict Breast Cancer Outcome-report from a Dual Institution Expirience in Serbia J BUON 2015; 20(6): 1407-13

 

Matovina-Brko G, Nikolin B, Popovic L, Nikin Z, Popovic-Petrovic S, Jovanovic D Paratesticular rhabdomyosarcoma of a young adult Contemp Oncol (Pozn). 2015;19(3):252-6.

 

Jovanovic D,Petrovic D, Popovic L Target therapy for patients with Non-Hodgkin Lymphomas 3rd Congress of Hematologist Serbia 2015 PP24: 70-71

 

  1. O. Markovic, L. Popović, Marisavljevic, J. Hajder R., Živković, N. Stanisavljevic, D. Jovanovic, B. Filipovic, D. Stanisavljevic, G. Matovina-Brko, T. Matkovic, , M. Todorović, D. Petrovic, B. Mihaljevic Prognostic Impact Analysis of absolute lymphocyte count(ALC) and absolute monocyte count (AMC) in patients with Diffuse Large B-Cell Lymphoma 3rd Congress of Hematologist Serbia 2015 OP23: 122

 

S.Popovic, B.Mihaljevic, N.Vlaisavljevic, L.Popovic, S.Salma, D.Agic, R.Milosevic,M.Smiljanic, S.Sretenovic, P.Djurdjevic,O.Markovic, J.Hajder, N.Govedarevic, D.Zivic, I. Savic, D.Jovanovic, N.Andjelkovic, T. Vukicevic, D.Marisavljevic Rituximab in the treatment of stge III and IV Follicular Lymphoma: Serbian Lymphoma Study Group Reflekt 1 results 3rd Congress of Hematologist Serbia 2015 OP25: 123

 

Popovic L, Matovina-Brko G. Anti-PD1/PD-L1 checkpoint inhibitors: a new frontier in cancer immunotherapy The second congress of the Serbian association for cancer research Proceedings book 2015 OP04: 14-17

 

Popovic L. Breast Cancer in very young woman X UMOS Conference Proceedings Book 2015

 

Popovic L. Target therapy in the treatment of Hodgkin Lymphoma VI NSOC Proceedings Book 2015

Popovic L, Jovanovic D, Knezevic-Usaj S, Nikin Z, Popovic Dj, Matovina-Brko G, Popovic M, Petrovic D The Expression of Molecular Markers As a Prognostic Factor of Diffuse Large B-Cell Lymphoma Treatment in Rituximab Era 1st ESHInternational Conference on New Concepts in B Cell Malignancies: From Molecular Pathogenesis to Personilized Treatment Abstr 2292 2014.

Popovic L., Jovanovic D., Petrovic D., Nikin Z., Matovina-Brko G., Trifunovic J., Kolarov-Bjelobrk I. Concurrent Chronic LymphocyticLeukemia And Merkel Cell Carcinoma In Primary Skin Tumor And Metastatic Lymph Node Indian J Hematol Blood Transfus 2014 Sep;30(Suppl 1):422-4. 

 

Popovic L, Trifunovic J, Pesic J, Matovina-Brko G, Kolarov-Bjelobrk I, Memisevic N, Jovanovic D Male Breast Cancer In The Era OfModern Therapies: Serbian Single Centre Experience Report Breast J 2014 Apr 8. May;20(3):329-30

 

  1. O. Markovic, L. Popović, Marisavljevic, D. Jovanovic, B. Filipovic, D. Stanisavljevic, G. Matovina-Brko, J. Hajder, T. Matkovic, R. Živković, N. Stanisavljevic, M. Todorović, D. Petrovic, B. Mihaljevic Comparison of prognostic impact of absolute lymphocytecount (ALC), absolute monocyte count (AMC), ALC/AMC prognostic score and ALC/AMC ratio in patients with diffuse large B celllymphoma Eur J Intern Med 2014 Mar;25(3):296-302.

 

  1. L.Popovic, O.Markovic, D. Jovanovic, D. Marisavljevic, D. Petrovic, B. Mihaljevic, Z. Nikin, T. Matkovic, G. Matovina-Brko,R. Zivkovic  Differences in baseline characteristics and survival rates between GCB and non-GCB diffuse large B-cell lymphomatreated with rituximab based immunochemotherapy EJC Suppl 2013 ECCO-ESMO abstract 3629

 

  1. L.Popovic, O.Markovic, D. Jovanovic, D. Marisavljevic, D. Petrovic, B. Mihaljevic, M. Popovic, T. Matkovic, G. Matovina-Brko,R. Zivkovic CD5-positive versus CD5-negative diffuse large B-cell lymphoma treated with immunochemotherapy: Is there adifference? EJC Suppl 2013 ECCO-ESMO abstract 3630

 

  1. L.Popovic, Z.Nikin, D. Jovanovic, S. Knezevic-Usaj, M. Popovic, G. Matovina-Brko BAFF, TACI and BCMA receptors expression andtheir impact on survival of patients with diffuse large b-cell lymphoma EJC Suppl 2013 ECCO-ESMO abstract 3633

 

 

Matovina-Brko G., Ruzic M., Fabri M., Popovic L., Kolarov-Bjelobrk I., Trifunovic J., Petkovic D. Treatment of acute hepatitis C in breat cancer patient J chemother 2014 Jun;26(3):180-3

 

MatovinaBrko G, Nikolin B, Popovic L, Nikin Z, Jovanovic D, Popovic-Petrovic S. Paratesticular rhabdomyosarcoma of a youngadult: a case report with review of the literature. Contemporary Oncology 2013 (ahead of print)

 

Markovic O, Popovic L, Marisavljevic D, Jovanovic D, Mihaljevic B, Stanisavljevic D, Hajder J, Zivkovic R, Petrovic D, StanisavljevicN, Matovina-Brko G, Todorovic M, Bila J Prognostic Significance Of Low Lymphocytes Count In The Patients With Diffuse Large BCell Lymphoma (DLBCL) Haematologica 2013 (EHA Abstract)

 

  1. B. Mihaljevic, D. Jovanovic, N. Andjelkovic, S. Popovic, T. Vukicevic, B. Andjelic,6 L. Popovic, M. Todorovic, N. Vlaisavljevic, A. Sretenovic, P. Djurdjevic, S. Sretenovic, S. Jankovic, O. Markovic, G. Marjanovic, S. Vrbic, J. Hajder, D. Zivic. Maximizingtherapeutic benefit of rituximab for

Relapsed/resistant follicular lymphoma: 2 years maintenance therapy results Hematol Oncol 2013: 31 (suppl. 1): 221

 

Lučić S, Peter A, Jovanović D, Popović L, Lučić A M, Kozarski D, Spirovski M Role Of 18f-Fdg Pet/Ct In Patients With FollicularLymphoma 2nd Balkan Congress of Nuclear Medicine, 2013.

 

 Popovic L, Popovic M, Jelic M Resistance to rituximab treatment: mechanisms and therapeutic inteventions. Med Danas 2013 (Ahead of print) (serbian)

 

Popovic L., Jovanovic D., Popovic Dj.  CD30-the head of the TNF familiy…or the successful story of brentuximab-vedotin Arch Oncol 2013; 21 (1): 17-19  

 

Jelic M, Jovanovic D, Popovic L, Striber-Devaja D Monoclonal antibodies at the Oncology Institute of Vojvodina-5 year expenditure Arch Oncol 2012; 20(3-4): 53-6

 

Popovic Dj, Popovic L, Stokic E, Tomic-Naglic D, Mitrovic M, Kovačev-Zavisic B

Influence of metformin therapy on breast cancer incidence and prognosis. Arch Oncol 2012; 20(3-4): 62-9

 

  1. L. Popovic, D. Jovanovic, D. Donat, D. Petrovic, T. Roganovic, J.-P. Lotz High dose chemotherapy with autologous stem cell transplantation for the patients with germ-cell cancer J BUON 2013; 18(1): 289-295

 

Lucic S, Peter A, Jovanovic D, Popovic L, Petrovic D, Lucic M  18F-FDG PET/CT diagnostic value in the temporal follow-up of lymphoma patients. Eur J Nucl Med Mol Imaging 2012; 39: S584

 

Petrovic D., Jovanovic D., Popovic L. Risk models for predicting chemotherapy-induced neutropenia in patients with solid tumors and malignant lymphoma Haematologica 2012 (EHA 2012; abstr 1784)

 

B Mihaljevic  ,D Antic ,B Andjelic ,L Popovic ,D Agic ,V Nikolic ,S Sretenovic ,V Vukovic New prognostic model in follicular non-Hodgkin lymphoma treated with rituximab chop: association of comorbidities with overall survival Haematologica 2012 (EHA 2012 abstr 1698)

B Andjelic ,D Antic ,V Nikolic ,L Popovic ,V Vukovic ,B Mihaljevic The impact of comorbidity burden on the overall survival in patients with diffuse large B-cell lymphoma Haematologica 2012 (EHA 2012 abstr 1701)

 

Petrovic-Popovic S, Tomic S, Nedeljkovic M, Popovic L, Matovina G Early rehabilitation in patients with breast carcinoma Vojnosanit Pregl. 2013 Apr;70(4):407-10

 

Popovic-Petrovic S, Nedeljkovic M, Popovic L, Petrovic V Secondary Lymphedema of the arm in breast carcinoma at the Oncology institute of Vojvodina: 2001 – 2006 Healthmed 2011; 5(6):

1719-25

 

Popovic L. , Jovanovic D., Petrovic D., Sundji A., Petrovic N., Roganovic T., Kukic B. Prognostic factors in the treatment of primary extranodal diffuse large B-cell lymphoma with rituximab-based immunochemotherapy Haematologica 2011; 96 (Supp 2):560

 

  1. Mihaljevic, D. Antic, B. Andjelic, M. Todorovic, T. Vukicevic, V. Nikolic, I. Pejcic, I. Petkovic, S. Popovic, L. Popovic, N. Andjelkovic, S. Sretenovic, M. Smiljenic, O. Markovic, J. Knezevic Prognostic significance of the Ki-67 index in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP-expirience of Serbian Lymhoma Study group Haematologica 2011; 96 (Supp 2): 575-6

 

  1. Mihaljevic, D. Antic, B. Andjelic, T. Vukicevic, V. Nikolic, I. Pejcic, I. Petkovic, S. Popovic, L. Popovic, N. Andjelkovic, S. Sretenovic, D. Lekovic, M. Smiljanic, O. Markovic, V. Knezevic, V. Kecman Characteristics of 917 Non-Hodgkin’s lymphoma patients in Serbia according to the WHO classification of lymphoid neoplasms-LIRA national register-basd study Ann Oncol 2011; 22 (Supp 4): iv204

 

  1. Mihaljevic, B. Andjelic, D. Antic, M. Todorovic, T. Vukicevic, V. Nikolic, I. Pejcic, I. Petkovic, S. Popovic, I Savic., L. Popovic, N. Andjelkovic, S. Sretenovic, J. Knezevic, V. Kecman Diffuse large B-cell lymphoma: germinal center vs non germinal center-treatment response on immunochemotherapy. Serbian Lymphoma Study group Ann Oncol 2011; 22 (Supp 4):iv224-5

 

Jovanovic D., Popovic L. et al Role of PET/CT in diagnosis and treatment of Lymphoma Haematology Congress of Bosnia and Herzegovina, Sarajevo, May 2011.

 

Jovanovic Da, Petrovic D., Popovic L., Bjelobrk-Kolarov I., Jovanovic Du. Thromboprophylaxis in hospitalized cancer patients Hematol Rep 2011; 3(Supp 1): 19

 

Stankov K., Bogdanovic G., Kojic V, Stankov S., Jojic N., Popovic L., Popovic S. Expression analysis of genes involved in epigenetic regulation and apoptosis in human malignant cell lines treated by 5-Azacitidine J BUON 2011;16 (1):116-122

  1. L. Popovic, D. Jovanovic, D. Donat, D. Petrovic, T. Roganovic, J.-P. Lotz High-dose chemotherapy with autologous stemcell support for the heavily pretreated patients with germ cell tumours: a Serbian single-centre first-experience reportBone Marrow Transpl 2011; 46(Supp 1): 385
  2. L. Popovic, D. Jovanovic, D. Petrovic, A. Sundji, N. Petrovic, T. Roganovic, B. Kukic Treatment of Primary ExtranodalDiffuse Large B-cell Lymphoma with Immunochemotherapy-Our Expirience 2nd Serbian Heamatology Congress/6thBalkan Day of Haematology Abstract Book Nov 2011:172.

 

  1. L. Popovic, D. Jovanovic, D. Petrovic, N. Petrovic, A. Sundji, T. Roganovic, G. Matovina-Brko Significance of StandardPrognostic Scores (IPI and R-IPI) in Prognosis of Diffuse Large B-cell Lymphoma Patients treated withImmunochemotherapy 2nd Serbian Heamatology Congress/6th Balkan Day of Haematology Abstract Book Nov 2011:173.

 

  1. B. Mihaljevic, D. Jovanovic, N. Andjelkovic, S. Popovic, T. Vukicevic, B. Andjelic, L. Popovic, M. Todorovic, N. Vlaisavljevic, A. Sretenovic, P. Djurdjevic, S. Sretenovic, S. Jankovic, O. Markovic, G. Marjanovic, S. Vrbic, J. Hajder, D. Zivic Rituximab incombination with Chemotherapy in Patients with Relapsed/Refractory Follicular NHL-Serbian Lymphoma Study GroupExpirience. 2nd Serbian Heamatology Congress/6th Balkan Day of Haematology Abstract Book Nov 2011:166.

 

  1. Agic, I. Savic, S. Popovic, I. Percic, V. Kvrgic, B. Sekulic, B. Andjelic, D. Antic, L. Popovic, D. Jovanovic, T. Vukicevic, N. Andjelkovic, S. Vrbic, V. Nikolic, S. Sretenovic, B. Mihaljevic Spread of Diffuse Large B-cell Lymphoma in Serbian Patients 2nd Serbian Heamatology Congress/6th Balkan Day of Haematology Abstract Book Nov 2011:20-22

 

  1. Nikolic, D. Antic, B. Andjelic, M. Todorovic, T. Vukicevic, I. Pejcic, I. Petkovic, S. Popovic, L. Popovic, N. Andjelkovic, S. Sretenovic, O. Markovic, J. Knezevic, B. MIhaljevic Prognostic significance of Ki-67 index in Patients with Diffuse Large B-cell Lymphoma treated with Rituximab plus CHOP-Serbian Lymphoma Study Group Expirience 2nd Serbian Heamatology Congress/6th Balkan Day of Haematology Abstract Book Nov 2011:23-25

 

  1. Sretenovic, N. Andjelkovic, D. Antic, B. Andjelic, T. Vukicevic, V. Nikolic, S. Popovic, L. Popovic, O. Markovic, J. Knezevic, B. Mihaljevic Pospective non-selective Study of patients with Lymphoproliferative Neoplasms in Serbia-LIRA National Register 2nd Serbian Heamatology Congress/6th Balkan Day of Haematology Abstract Book Nov 2011:26-29.

 

  1. Andjelic, D. Antic, V. Nikolic, L. Popovic, V. Vukovic, B. Mihaljevic Prognostic Significance of Comorbidity Indeces in Diffuse Large B-Cell Lymphoma 2nd Serbian Heamatology Congress/6th Balkan Day of Haematology Abstract Book Nov 2011:34-36.B. Mihaljevic, D. Antic, B. Andjelic, D. Lekovic, D. Jovanovic, L. Popovic, T. Vukicevic, I. Pejcic, N. Andjelkovic, P. Djurdjevic, O. Markovic High ki-67 protein expression as prognostic factor in diffuse large B-cell lymphoma – experience of Serbian Lymphoma study Group Abstract 416; International Society of Haematology Congress, Jerusalem , Israel 2010.

 

Popovic L, Jovanovic D., Matovina-Brko G., Petrovic D., Nikin Z, Roganovic T. Primary diffuse large B-cell lymphoma of thebreast Arch Oncol 2009; 17 (3-4): 80-2

 

Grgic Z, Oros A, Rasic D, Popovic L, Popovic M Ocular malignant melanoma in pregnancy: is a happy ending possible? Arch Oncol 2009; 17 (3-4): 83-5

 

Popovic L, Jovanovic D, Petrovic D, Matovina G, Roganovic T. ALK-negative large cells lymphoma in sceletal muscle-casereport. Medicina Danas 2009; 8(7-9): 249-54. (serbian)

 

Stankov K, Tauszig-Delamasure S, Bogdanovic G, Popovic L, Stankov S, Sylvisus N, Popovic S, Mehlen P.  Expression of the genes involved in apoptosis, proliferation and endoplasmic reticulum stress in ionomycin/PMA treated Jurkat cells EJC Supplements (2008), 6(12): 89-90.

 

Stankov, K; Bogdanovic, G; Popovic L; Popovic, S; Tauszig-Delamasure, S; Mehlen, P;

Sylvius,N Expression of c-kit/SCF tyrosine kinase signaling pathway and apoptotic genes in

ionomycin/PMA treated Jurkat cells EJC Supplements (2008), 6(9): 147-147

 

Andrijevic LJ, Aleksic L, Baltic M, Popovic L, Jovanovic D, Petrovic D, Matovina G. Enumeration of haematopoietic CD34+ stem cells by flowcytometry. Balkan flow users meeting Rovinj Croatia 2008.

 

Popovic L. Rituximab maintenance therapy in follicular lymphoma Arch Oncol 2008;16(1-2): 23. 0

 

Popovic L. Anti-CD20 MAB(s)…, but not…THERA. Arch Oncol 2008; 16(1-2):23-24.

 

Popovic L., Jovanovic D., Petrovic D., Matovina G., Roganovic T. „Rituximab in combination with chemotherapy in treatment of diffuse large B-cell lymphoma: our expirience“Abstr.33 Bilt. Hematol 2007; 35(3): 86-100  (serbian)

 

Popovic L., Jovanovic D., Petrovic D., Matovina G., Roganovic T. „Breast involving lymphoma: report of four cases“ Abstr. 35 Bilt. Hematol 2007; 35(3): 86-100 (serbian)

 

Popovic L., Jovanovic D., Petrovic D., Matovina G., Roganovic T. „ALK-negative anaplastic

large T-cell lymphoma in a muscle: case report and review of literature“ Abstr. 44 Bilt. Hematol

2007; 35(3): 86-100  (serbian)

  

  1. Matovina G., Jovanovic D., Fabri M., Petrovic D., Popovic L., Roganovic T. „Heapatitis B

viral infection reactivation during induction lymphoma therapy: report of two cases“ Abstrakt br. 54 Bilt. Hematol 2007; 35(3): 86-100  (serbian)

    

Tešanovic S. Popovic L:. « Efficacy of lower dose capacitabine in metastatic breast cancer»

Sr. Kamenica 2006. (serbian)

 

Popovic L. «Quality of life in different insuline therapy regimen (CIT, MSII)» Limsc Leiden

Holland 2005.